Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker study of atezolizumab + bevacizumab + paclitaxel + carboplatin in driver-mutated advanced NSCLC after TKI failure
NL-OMON21412Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Feb 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab, bevacizumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC), sponsored by University Medical Center Groningen. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
atezolizumabbevacizumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON21412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21412.